Theriva Biologics, Inc.

NYSEAM:TOVX Stock Report

Market Cap: US$4.9m

Theriva Biologics Management

Management criteria checks 1/4

Theriva Biologics' CEO is Steve Shallcross, appointed in Jun 2015, has a tenure of 9.5 years. total yearly compensation is $1.27M, comprised of 48.3% salary and 51.7% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth $17.60K. The average tenure of the management team and the board of directors is 9.5 years and 2.6 years respectively.

Key information

Steve Shallcross

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage48.3%
CEO tenure9.5yrs
CEO ownership0.4%
Management average tenure9.5yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Mar 07
David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

Feb 04
Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

CEO Compensation Analysis

How has Steve Shallcross's remuneration changed compared to Theriva Biologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$27m

Jun 30 2024n/an/a

-US$22m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$614k

-US$18m

Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$1mUS$585k

-US$20m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$1mUS$585k

-US$23m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$1mUS$565k

-US$13m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$1mUS$550k

-US$16m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$26m

Mar 31 2019n/an/a

-US$27m

Dec 31 2018US$963kUS$489k

-US$25m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$22m

Mar 31 2018n/an/a

-US$22m

Dec 31 2017US$799kUS$347k

-US$22m

Compensation vs Market: Steve's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Shallcross (63 yo)

9.5yrs

Tenure

US$1,271,913

Compensation

Mr. Steven A. Shallcross, also known as Steve, CPA, was an Independent Director of Forza X1, Inc. since December 2021. He served as Independent Director at Twin Vee Powercats Co. since April 8, 2021 until...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Shallcross
CEO, CFO9.5yrsUS$1.27m0.36%
$ 17.6k
Vince Wacher
Head of Product & Corporate Developmentno datano datano data
Michael Kaleko
Senior Vice President of Research & Development12.2yrsno datano data
Ramon Alemany
Senior VP of Discovery & Chairman of Scientific Advisory Board1.6yrsno datano data

9.5yrs

Average Tenure

Experienced Management: TOVX's management team is seasoned and experienced (9.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Shallcross
CEO, CFO6yrsUS$1.27m0.36%
$ 17.6k
Ramon Alemany
Senior VP of Discovery & Chairman of Scientific Advisory Board2.6yrsno datano data
John Monahan
Independent Director4.1yrsUS$110.51k0%
$ 0
Thomas Dubensky
Member of Scientific Advisory Board2.6yrsno datano data
Jeffrey Kraws
Independent Non-Executive Chairman18.9yrsUS$220.01k0.00093%
$ 45.5
Mark Blumenkranz
Member of Scientific Advisory Board2.6yrsno datano data
Jeffrey Wolf
Independent Director18.9yrsUS$117.51k0%
$ 0
Josep Tabernero Caturla
Member of Scientific Advisory Board2.6yrsno datano data
Ennio Chiocca
Member of Scientific Advisory Board2.6yrsno datano data
Daniel DiMaio
Member of Scientific Advisory Board2.6yrsno datano data

2.6yrs

Average Tenure

64.5yo

Average Age

Experienced Board: TOVX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:28
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theriva Biologics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Keay NakaeAscendiant Capital Markets LLC
Timothy ChiangBTIG